PATENT COOPERATION TREATY

PCT

REC'D 10 JAN 2005

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

									
Applicant's or agent's file reference TX/4-32852A		FOR FURTHER A	CTION	See Form PCT/IPEA/416					
International application No. International filing date PCT/EP2004/000354 19.01.2004		(day/month/year)	Priority date (day/month/year) 20.01.2003						
International Patent Classification (IPC) or national classification and IPC A61K9/14									
Applicant NOVARTIS AG									
This report is the International preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36.									
2. This REPOR	consists of a total	of 6 sheets, including t	his cover sheet.						
3. This report is	also accompanied t	y ANNEXES, comprisi	ng:						
'	· ·	o the International Bure	•	, as follows:					
□ sh ar	sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).								
] be	<u>-</u>								
seque									
,		,							
4. This report co	ntains indications re	elating to the following it	ems:						
図 Box No. I	Basis of the opi	nion							
☐ Box No. II	Priority								
☐ Box No. Ii	Non-establishm	ard to noveity, inventiv	e step and industrial applicability						
☐ Box No. IV		invention							
⊠ Box No. V	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement								
☐ Box No. V	l Certain docume	ents cited		•					
☐ Box No. V	☐ Box No. VII Certain defects in the international application								
☐ Box Nọ. V	☐ Box No. VIII Certain observations on the international application								
Date of submission of the demand			Date of completion of	this report					
24.07.2004			07.01.2005						
Name and malling ad	iress of the internation	nal	Authorized Officer						
preliminary examining	authority: an Patent Office			Section same					
D-80298 Munich			Baston, E	(0)) }					
Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465			Telephone No. +49 89	2399-8229					

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/000354

	Box No	o. I Basis of the report				
 With regard to the language, this report is based on the international application in the language in filed, unless otherwise indicated under this item. 						
	wh	is report is based on translations from the original language into the following language , ich is the language of a translation furnished for the purposes of:				
	international search (under Rules 12.3 and 23.1(b)) publication of the international application (under Rule 12.4) international preliminary examination (under Rules 55.2 and/or 55.3)					
2. With regard to the elements* of the international application, this report is based on (replacement sheets have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in report as "originally filed" and are not annexed to this report):						
	Descri	otion, Pages				
	1-20	as originally filed				
	Claims	, Numbers				
	1-11	as originally filed				
	Drawin	gs, Sheets				
	1/6-6/6	as originally filed				
	□а	sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing				
3.		ne amendments have resulted in the cancellation of:				
		the description, pages the claims, Nos.				
		the drawings, sheets/figs the sequence listing (specify):				
		any table(s) related to sequence listing (specify):				
4.	had no	nis report has been established as if (some of) the amendments annexed to this report and listed below of been made, since they have been considered to go beyond the disclosure as filed, as indicated in the emental Box (Rule 70.2(c)).				
		the description, pages the claims, Nos.				
		the drawings, sheets/tigs				
		the sequence listing (specify): any table(s) related to sequence listing (specify):				
	* 7	f item 4 applies, some or all of these sheets may be marked "superseded."				

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/000354

	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability						
1.	The obvi	e questions whether the claimed invention appears to be novel, to involve an inventive step (to be non- vious), or to be industrially applicable have not been examined in respect of:					
		the entire international application,					
	×	claims Nos. 7-11					
		because:					
		the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (specify):					
		the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):					
		the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.					
	×	no international search report has been established for the said claims Nos. 7-11					
		the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:					
		the written form		has not been furnished			
				does not comply with the standard			
		the computer readable form		has not been furnished			
				does not comply with the standard			
	ū	the tables related to the nucleotide and/or amino acid sequence listing, if in computer readable form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.					
		See separate sheet for further of	dețail	ds .			

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/000354

_	Box No. IV Lack of unity of invention							
1.		 In response to the invitation to restrict or pay additional fees, the applicant has: □ restricted the claims. □ paid additional fees. □ paid additional fees under protest. ☑ neither restricted nor paid additional fees. 						
2.		This Authority found that the requirement of unity of invention is not complied with and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.						
3.	This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is						3.2 and 13.3	
		complied	d with.					
	Ø	not com	plied with for the follo	wing re	easons:			
		see sep	arate sheet					
4.	Coi	nsequentl	y, this report has bee	n estat	olished in re	spect of the f	following parts of the international	application:
		□ all parts.						
	\boxtimes	the parts	s relating to claims No	s. 1-6	-		•	
			•			•		
	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement							or industrial
1.	Sta	tement						
	Nov	Novelty (N)		Yes: No:	Claims Claims	1-6		
	Inventive step (IS)		Yes: No:	Claims Claims	1-6			
	Ind	ustrial ap	plicability (IA)	Yes: No:	Claims Claims	1-6		
2.	Cita	ations and	d explanations (Rule 7	70.7):	·			

see separate sheet

Re Item III.

Due to non-establishment of search report no opinion is provided for claims 7-11.

Re Item IV.

The separate inventions/groups of inventions are:

1-6

Process for modifying the crystal habbit of an acicular drug

7-10

Crystals of a specific aspect ratio

11

Crystal modifications of mycophenolic acid or sodium mycophenolate

They are not so linked as to form a single general inventive concept (Rule 13.1 PCT) for the following reasons:

Claim 1 relates to a process for the provision of crystalline compounds resulting in a specific length/width ratio. Moreover crystals and crystal modifications are claimed that possibly can be obtained by the given process. For the purpose of unity of invention it is required to define a single general inventive concept which represents a contribution over the prior art. Thus a special technical feature needs to be present in all subjectmatter claimed. In the present case it is considered that the technical problem can be formulated as how to provide a method for modifying the crystal habit of compounds. The solution provided by the present application is a process which is known from document WO9967236. Additionally it has to be stated that crystals obtained by this process are neither endowed with intrinsic properties due to their preparation procedure nor do these crystals have a specific activity. Crystals of a defined shape could also be obtained by a different process. Thus there is also a priori non-unity between group 1 and groups 2,3. Due to the fact that crystals of a specific aspect ratio are known from document WO9967236 there is no unifying feature to be identified between group 2 and group 3 of the application. Affitonally it has to be stated that crystal modifications of mycophenolic acid and sodium mycophenolate according to claim 11 are not characterized by their aspect ratio.

In view of the cited document of the prior art and the a priori objections mentioned above, possible contributions over the prior art diverge in three different directions and

are thus not so linked to form a single inventive concept which would support the unity of invention.

Re Item V.

- 1 The following document is referred to in this communication:
 - D1: WO 99/67236 A (SANOFI SYNTHELABO; FRANC BRUNO (FR); HOFF CHRISTIAN (FR); MONNIER OLI) 29 December 1999 (1999-12-29)
- 2 INDEPENDENT CLAIM 1
- 2.1 The present application does not meet the criteria of Article 33(1) PCT, because the subject-matter of claim 1 is not new in the sense of Article 33(2) PCT. Document D1 discloses already a process (compare page 15) which employ temperature oscillation in order to arrive at modified crystal forms.
- 3 DEPENDENT CLAIMS 2-6

Dependent claims 2-6 do not contain any features which, in combination with the features of any claim to which they refer, meet the requirements of the PCT in respect of novelty and/or inventive step (Article 33(2) and (3) PCT).

4 Clarity

Claim 1 is not acceptable in view of Art. 6 PCT, since the expression acicular drug is not suitable to clearly define the shape of the compound.